Mineralocorticoid Receptor Antagonists and the Metabolic Syndrome
نویسندگان
چکیده
منابع مشابه
Mineralocorticoid receptor antagonists for the treatment of hypertension and the metabolic syndrome.
I ncreasing evidence suggests a link between the metabolic syndrome and aldosterone. Patients with obesity and the metabolic syndrome have been found to have increased adrenal production of aldosterone and increased cortisol levels , whereas weight reduction is associated with a decrease in aldosterone. 6 A high-fat diet has been shown to lead to an upregulation of mineralocorticoid expression,...
متن کامل30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
The cDNA of the mineralocorticoid receptor (MR) was cloned 30 years ago, in 1987. At that time, spirolactone, the first generation of synthetic steroid-based MR antagonists (MRAs), which was identified in preclinical in vivo models, had already been in clinical use for 30 years. Subsequent decades of research and development by Searle & Co., Ciba-Geigy, Roussel Uclaf and Schering AG toward iden...
متن کاملMineralocorticoid receptor antagonists in dialysis patients
Mineralocorticoid receptor (MR) antagonists are known to have beneficial effects in patients with cardiovascular disease without renal failure. However, there have been few published studies on the effectiveness of MR antagonists in dialysis patients, and most of the studies were small-sized. The present review focuses on the effectiveness of MR antagonists and the risk of hyperkalemia in dialy...
متن کاملThe Metabolic Effects of Mineralocorticoid Receptor Antagonists in Heart Failure Patients
Heart failure (HF) remains a leading cause of cardiovascular morbidity and mortality worldwide. Mineralocorticod receptor (MR) antagonists (spironolactone and eplerenone) have been studied in HF patients and in patients with acute coronary syndrome or post-myocardial infarction and left ventricular (LV) dysfunction, as well as hypertensive subjects without HF symptoms. It has suggested that min...
متن کاملCardiac Hypertrophy and Fibrosis in the Metabolic Syndrome: A Role for Aldosterone and the Mineralocorticoid Receptor
Obesity and hypertension, major risk factors for the metabolic syndrome, render individuals susceptible to an increased risk of cardiovascular complications, such as adverse cardiac remodeling and heart failure. There has been much investigation into the role that an increase in the renin-angiotensin-aldosterone system (RAAS) plays in the pathogenesis of metabolic syndrome and in particular, ho...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Hypertension Reports
سال: 2010
ISSN: 1522-6417,1534-3111
DOI: 10.1007/s11906-010-0126-2